Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)

7 juli 2026 bijgewerkt door: Pernille Kølbæk, Aarhus University Hospital

Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study

This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.

Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.

Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.

The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.

Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.

The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.

The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.

Studietype

Ingrijpend

Inschrijving (Geschat)

15

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Pernille Kølbæk, MD PhD
  • Telefoonnummer: 004561397432
  • E-mail: perpet@rm.dk

Studie Contact Back-up

  • Naam: Ana Lisa Carmo, Psychiatrist
  • Telefoonnummer: 0045 61155056
  • E-mail: ANAMAR@rm.dk

Studie Locaties

      • Aarhus N, Denemarken
        • Aarhus University Hospital
        • Contact:
          • Pernille Kølbæk, MD PhD
          • Telefoonnummer: 004561397432
          • E-mail: perpet@rm.dk
        • Contact:
          • Ana Lisa Carmo, Psychiatrist
          • Telefoonnummer: 0045 61155056
          • E-mail: ANAMAR@rm.dk
        • Hoofdonderzoeker:
          • Ana Lisa Carmo, Psychiatrist
      • Horsens, Denemarken
        • Regional Psychiatry Horsens
        • Contact:
          • Pernille Kølbæk, MD PhD
          • Telefoonnummer: 004561397432
          • E-mail: perpet@rm.dk
        • Contact:
          • Thea Grønfeldt, Psychiatrist
          • Telefoonnummer: 00457847 9258
          • E-mail: theafaer@rm.dk
        • Hoofdonderzoeker:
          • Pernille Kølbæk, MD PhD
      • Viborg, Denemarken
        • Regional Psychiatry Central Jutland
        • Contact:
          • Pernille Kølbæk, MD PhD
          • Telefoonnummer: 004561397432
          • E-mail: perpet@rm.dk
        • Hoofdonderzoeker:
          • Ana Lisa Carmo, Psychiatrist
        • Contact:
          • Ana Lisa Carmo, Psychiatrist
          • Telefoonnummer: 004561155056
          • E-mail: ANAMAR@rm.dk

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Age 18-70 years
  • ICD-10 criteria for PTSD (F43.1)
  • A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
  • Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
  • Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.

Exclusion Criteria:

  • Organic mental disorders (F0)
  • Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
  • Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
  • Active suicidality
  • Any ongoing involuntary/coercive measures
  • Any contraindications listed on the TMS Safety Checklist

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks. After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR. Participants with sufficient response continue EMDR treatment alone.
All enrolled participants begin standardized EMDR treatment. Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR. Participants who show sufficient improvement continue EMDR alone.
Andere namen:
  • Behavioral: Eye Movement Desensitization and Reprocessing (EMDR)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Drop-out
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
The primary outcome will be drop-out rates
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Treatment completion rates
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Symptom trajectories
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates
Tijdsspanne: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Changes in mental well-being
Tijdsspanne: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Pernille Kølbæk, Aarhus University Hospital
  • Hoofdonderzoeker: Ana Lisa Carmo, Aarhus University Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 juli 2026

Primaire voltooiing (Geschat)

1 juni 2027

Studie voltooiing (Geschat)

1 juni 2027

Studieregistratiedata

Eerst ingediend

16 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

7 juli 2026

Eerst geplaatst (Werkelijk)

9 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

9 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

7 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren